Experimental Chemo Combo for Colon Cancer D... ( TUESDAY April 3 (Heal...)

Experimental Chemo Combo for Colon Cancer Disappoints

Date:4/3/2012

TUESDAY, April 3 (HealthDay News) -- Adding the drug cetuximab (brand name Erbitux) to standard chemotherapy after surgery for stage 3 colon cancer did not improve disease-free survival in patients, a new study concludes.

Patients with stage 3 colon cancer who undergo surgery have a 50 percent chance of cure, and clinical trials have found that chemotherapy with the drugs leucovorin, fluorouracil and oxaliplatin (a regimen known as FOLFOX) after surgery can cut the odds for colon cancer's return.

Staging refers to the severity of cancer. A stage 3 cancer has spread nearby, while a stage 4 cancer has spread to another organ.

This study of almost 2,700 patients investigated the addition of cetuximab to the FOLFOX regimen and found that it provided no extra benefit.

Three-year disease-free survival for patients who received the FOLFOX regimen alone ranged from 67 percent to 75 percent, compared with 65 percent to 72 percent for those who also received cetuximab, the study found.

The study appears in the April 4 issue of the Journal of the American Medical Association.

The time to cancer recurrence and overall survival was similar in both groups, said Dr. Steven Alberts, of the Mayo Clinic in Rochester, Minn., and colleagues in a journal news release.

It's not clear why the addition of cetuximab to the FOLFOX regimen did not benefit patients, the researchers noted.

Dr. Richard Whelan, chief of colorectal surgery at St. Luke's-Roosevelt Hospital in New York City, explained that the drug had shown promise with other patients.

"Cetuximab was added to the FOLFOX regimen based on promising results noted when this agent was given to stage 4 colon cancer patients either alone or with other chemotherapy agents," said Whelan, who was not involved in the new study. "Unfortunately, what works in one setting may not prove equally effective in a different population of patients. Researchers wi
'/>"/>

4

GOOD

Page: 1 2
Related medicine news :

1. Experimental Pill May Ease Multiple Sclerosis Disability
2. Experimental Drug Shows Promise Against Cushings Disease
3. Experimental Drug Offers Hope for Rare Bone Disease: Study
4. Experimental Drug Shows Promise Against Type 2 Diabetes
5. First-in-human drug for malignant glioma available in experimental trial
6. Experimental Drug Might Beat Aspirin in Preventing Repeat Strokes: Study
7. Experimental Drugs Do Battle Against Advanced Prostate Cancer
8. Experimental Blood Thinner Given Before Surgery Shows Benefit
9. Wolfson Foundation awards £20 million to UCL for experimental neurology center
10. Novel experimental agent is highly active in CLL patients, interim study shows
11. Experimental Drug for Irregular Heart Rhythm Raises Death Risk: Study

Post Your Comments:

Related Image:

Experimental Chemo Combo for Colon Cancer Disappoints

(Date:5/21/2013)... Modern couples have countless strains ... Counseling’s Sexuality and Relationship Workshops, couples are learning ... healthier habits for their relationship. There are both ... and individuals at Texas Counseling. Their goal is ... skills to develop long term solutions. , ...

(Date:5/21/2013)... Serum Repository (DoDSR), University of Cincinnati (UC) researchers have ... (IBD), which could help with earlier diagnosis and intervention ... This finding, the first of its kind and led ... podium presentation by staff from Walter Reed National Military ... May 18-21 in Orlando, Fla. , The DoDSR ...

(Date:5/21/2013)... 21, 2013 The Las Vegas personal injury ... announce that Crawford Gates, a senior at Coronado High School, ... scholarship essay contest . As the winner of the essay ... contest started on Dec. 1, 2012 and ran through April ... submit a three-page minimum essay on “The Role of the ...

(Date:5/21/2013)... Durham, NC (PRWEB) May 21, 2013 ... STEM CELLS Translational Medicine indicates that stem cells harvested ... from bone marrow in helping to modulate the body’s ... implications in developing new stem-cell-based therapies, as adipose tissue-derived ... body than those found in bone marrow and can ...

(Date:5/21/2013)... (PRWEB) May 22, 2013 About one ... the Fertility Clinics industry one of the ... assists patients who are unable to conceive naturally through ... popular of which is in-vitro fertilisation (IVF) cycles. Over ... cycles in Australia has increased by 4.4% per annum ...

Breaking Medicine News(10 mins):Health News:Workshops Offered To Identify Underlying Challenges That Put Strain On Relationships 2 Health News:Biomarkers discovered for inflammatory bowel disease 2 Health News:Benson, Bertoldo, Baker & Carter is Pleased to Announce the Winner of its First Annual College Scholarship Essay Contest 2 Health News:Stem Cells from Fat Outperform Those from Bone Marrow in Fighting Disease 2 Health News:Stem Cells from Fat Outperform Those from Bone Marrow in Fighting Disease 3 Health News:Fertility Clinics in Australia Industry Market Research Report Now Available from IBISWorld 2 Health News:Fertility Clinics in Australia Industry Market Research Report Now Available from IBISWorld 3

[0] Workshops Offered To Identify Underlying Challenges That Put Strain On Relationships [0] Biomarkers discovered for inflammatory bowel disease [0] Benson, Bertoldo, Baker & Carter is Pleased to Announce the Winner of its First Annual College Scholarship Essay Contest [0] Stem Cells from Fat Outperform Those from Bone Marrow in Fighting Disease [0] Fertility Clinics in Australia Industry Market Research Report Now Available from IBISWorld

... SHENZHEN, China, Aug. 10 /PRNewswire-Asia-FirstCall/ -- Mindray Medical,International Limited (NYSE: ... devices worldwide announced today its selected unaudited,financial results for the second ... Highlights for Second Quarter and First Half 2009, ... an increase of, 9.9% over ...

... , , FRAMINGHAM, Mass. ... HTWR ) (ASX: HIN) today announced that it has entered into ... United States to sell approximately 2.5 million shares of its common ... have agreed to purchase the shares at a purchase price of ...

... Study found women with familial history of disease were protected ... their babies even for short periods of time may lower ... a family history of the disease. , "We saw ... with a family history who had ever breast-fed," stated Dr. ...

... , , WASHINGTON, Aug. ... health insurance is an immigrant (legal or illegal) or the U.S.-born ... account for one-fourth of those on Medicaid. While there has ... proposed government insurance plans, the enormous impact of immigration, both legal ...

... Search for Family of the Year -- Winning Family Receives Trip to ... , , GREENWICH, Conn., Aug. 10 Think your family ... part of its Pure Life / B e st ... Ne s tle(R) Pure Life(R) bottled water , ...

... , PALO ALTO, Calif., Aug. 10 ... will report its second quarter 2009 financial results on Tuesday, August 11, ... to discuss the results, provide guidance for 2009, and give a company ... Time. , , The live webcast and press release ...

Mindray Announces Second Quarter 2009 Financial Results HeartWare International, Inc. Announces US$55 Million Financing Breast-Feeding May Lower Breast Cancer Risk The Elephant in the Room: Panel on Immigration's Impact on Health Care Reform Could Your Family Be The 'Family of the Year?'Jazz Pharmaceuticals to Announce Second Quarter Financial Results on August 11, 2009

(Date:5/21/2013)... 2013 Tom Daulton, CEO of Mammotome, a division of ... by the Cincinnati chapter of the ... another local top executive who is also a breast cancer ... Endo-Surgery in March of 2010. Daulton will be presented with ... by Huntington Bank, on May 22. The ACG ...

(Date:5/21/2013)... 2013 LCA-Vision Inc. (NASDAQ: LCAV ), a ... Plus ® brand, announces that all nominees to the company,s ... annual meeting of stockholders. These Directors are: , ... Bahl & Gaynor Investment Counsel , John ... Edgar F. Heizer III , Chairman of ...

(Date:5/21/2013)... Kepner-Tregoe (KT), the global capability development ... Chris Geraghty has been ... than 20 years serving the industrial sector, holding ... succeeds Ray Baxter , who ... the Board and CEO. (Logo: ...

Breaking Medicine Technology:Tom Daulton, Mammotome CEO, Named ACG Dealmaker of the Year 2 Tom Daulton, Mammotome CEO, Named ACG Dealmaker of the Year 3 LCA-Vision Reports on Annual Meeting of Stockholders 2 LCA-Vision Reports on Annual Meeting of Stockholders 3 LCA-Vision Reports on Annual Meeting of Stockholders 4 Kepner-Tregoe, Inc. Promotes Chris Geraghty to Chief Executive Officer 2 Kepner-Tregoe, Inc. Promotes Chris Geraghty to Chief Executive Officer 3

[0] Tom Daulton, Mammotome CEO, Named ACG Dealmaker of the Year [0] LCA-Vision Reports on Annual Meeting of Stockholders [0] Kepner-Tregoe, Inc. Promotes Chris Geraghty to Chief Executive Officer

... 2011 Reportlinker.com announces that a ... in its catalogue: ... – Bone Grafting and Hyaluronic Acid ... http://www.reportlinker.com/p0488653/European-Markets-for-Orthopedic-Biomaterials-2011-–-Bone-Grafting-and-Hyaluronic-Acid-Viscosupplementation-15-Countries.html The ...

... (Nasdaq: STXS ) continued leadership in the ... will again be prominently detailed in the scientific program ... San Francisco, California. Ten podium presentations and ten posters ... of magnetic navigation in the treatment of a variety ...

Reportlinker Adds European Markets for Orthopedic Biomaterials 2011 - Bone Grafting and Hyaluronic Acid Viscosupplementation (15 Countries)Stereotaxis' Continued Leadership in Scientific Outcome Data Prominently Displayed with Multiple Key Presentations at HRS 2011

... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...

... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...

... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...

Medicine Products:

Enterococcal Susceptibility Panel Entamoeba histolytica (amebiasis), Antibody, IgG by ELISA Entamoebahistolytica Antigen, EIA Enkaid